(Q46139484)

English

Molecular interaction of imino sugars with human alpha-galactosidase: Insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease

scientific article published on 31 January 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19181556

Molecular interaction of imino sugars with human alpha-galactosidase: Insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19181556

molecular chaperones

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

molecular interaction

1 reference

based on heuristic

inferred from title

author name string

Kanako Sugawara

1

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19181556

Youichi Tajima

2

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19181556

Ikuo Kawashima

3

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19181556

Takahiro Tsukimura

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19181556

Seiji Saito

5

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19181556

Kazuki Ohno

6

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19181556

Kunihiko Iwamoto

7

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19181556

Toshihide Kobayashi

8

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19181556

Kohji Itoh

9

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19181556

Hitoshi Sakuraba

10

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19181556

publication date

31 January 2009

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19181556

Molecular Genetics and Metabolism

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19181556

96

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19181556

4

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19181556

233-238

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19181556

The molecular defect leading to Fabry disease: structure of human alpha-galactosidase

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.12.017

7 January 2021

High incidence of later-onset fabry disease revealed by newborn screening

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.12.017

7 January 2021

Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.12.017

7 January 2021

A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.12.017

7 January 2021

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.12.017

7 January 2021

A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.12.017

7 January 2021

A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.12.017

7 January 2021

Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.12.017

7 January 2021

Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.12.017

7 January 2021

Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.12.017

7 January 2021

Binding parameters and thermodynamics of the interaction of imino sugars with a recombinant human acid alpha-glucosidase (alglucosidase alfa): insight into the complex formation mechanism

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.12.017

7 January 2021

Point mutations in the upstream region of the ?-galactosidase A gene exon 6 in an atypical variant of Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.12.017

7 January 2021

Galactose stabilizes various missense mutants of alpha-galactosidase in Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.12.017

7 January 2021

On the stringent requirement of mannosyl substitution in mannooligosaccharides for the recognition by garlic (Allium sativum) lectin. A Surface Plasmon Resonance Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.12.017

7 January 2021

Kinetic and thermodynamic characterization of HIV-1 protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.12.017

7 January 2021

Chemical chaperones improve transport and enhance stability of mutant alpha-glucosidases in glycogen storage disease type II

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.12.017

7 January 2021

Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.12.017

7 January 2021

Chemical chaperones increase the cellular activity of N370S beta -glucosidase: a therapeutic strategy for Gaucher disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.12.017

7 January 2021

Structural characterization of mutant alpha-galactosidases causing Fabry disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.12.017

7 January 2021

Do enthalpy and entropy distinguish first in class from best in class?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.12.017

7 January 2021

Identifiers

10.1016/J.YMGME.2008.12.017

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19181556

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 December 2017

http://europepmc.org/abstract/MED/19181556

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46139484&oldid=2094275972"